seekingalpha.com
/1 month ago
Latest updates for Alks
Fresh curated links around ALKS are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow
- Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line
- Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 month ago
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line...
seekingalpha.com
/1 month ago
Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL
fool.com
/1 week ago
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
qchron.com
/1 month ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, April 7, 2026 /PRNewswire/ --
fool.com
/3 weeks ago
Amylyx (AMLX) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...
fiercebiotech.com
/1 month ago
Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure
Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study.
seekingalpha.com
/1 month ago
Alaska Air expects Q2 EPS loss of about $1 while suspending full-year guide amid fuel volatility
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Alks
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
fiercebiotech.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source
qchron.com
Recent coverage from public sources
Public source